802
+3.62%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Renascience
Its shares trade on Tokyo Stock Exchange under the ticker 4889.T. It has been listed since 24 September 2021. In the fiscal year to 31 March 2026, it reported revenue of ¥68.6m and a net loss of ¥301.3m. At that date it held total assets of ¥3.50bn and shareholders' equity of ¥3.32bn.
Renascience, Inc. engages in the development and sale of pharmaceuticals. The company is headquartered in Chuo-Ku, Tokyo-To. The company went IPO on 2021-09-24. The firm is engaged in the research and development of various modalities (pharmaceuticals, medical devices, artificial intelligence (AI) solutions) to solve problems in the medical field, in collaboration with physicians. The firm is engaged in the development of drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The firm is also engaged in the solve of other medical issues such as diseases of women and children, and COVID-19 infection.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 Sept 2021
- Employees
- 3
- Website
- renascience.co.jp ↗
Leadership
Pay as last reported
- Koji NaitoPresident & Representative Director, since 2019
- Sho KatoDirector, Head-Research & Development, since 2018
- Kazuhiro IkedaDirector & Manager-Administration, since 2020
- Toshio Miyata, MD, PhDChairman, since 2018
- Koji NaitoPresident & Representative Director, since 2019
- Sho KatoDirector, Head-Research & Development, since 2022
- Kazuhiro IkedaDirector & Manager-Administration, since 2020
- Mitsuru IchikawaIndependent Outside Director, since 2019
- Yasuo AzumaIndependent Outside Director, since 2019
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Renascience Inc. operates in the Health Care sector within the Pharmaceuticals industry.
- The company is headquartered in Chuo-Ku, Tokyo-To, Japan.
- Renascience develops pharmaceuticals and medical devices in collaboration with physicians.
Weaknesses
- The firm employs only 3 full-time employees.
- Renascience Inc. is listed on the Tokyo Stock Exchange under ticker 4889.T.
- The company went public in September 2021, indicating a relatively recent listing.
Opportunities
- Renascience engages in the research and development of artificial intelligence solutions.
- The firm develops drugs for four non-infectious aging-related diseases including cancer and diabetes.
- Renascience addresses other medical issues such as diseases of women and children.
Threats
- The company focuses on the development of drugs for respiratory diseases and cardiovascular diseases.
- Renascience Inc. is engaged in solving problems related to COVID-19 infection.
- The firm operates exclusively in Japan with its headquarters in Chuo-Ku.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.